Antibiotic Regimens for MRSA vs. MSSA Infections
For MSSA infections, use cefazolin or an antistaphylococcal penicillin (nafcillin/oxacillin) as first-line therapy; for MRSA infections, use vancomycin or daptomycin for serious infections, with oral alternatives (clindamycin, TMP-SMX, doxycycline, or linezolid) reserved for outpatient skin and soft tissue infections.
MSSA Treatment Algorithm
Invasive/Serious Infections (Bacteremia, Endocarditis, Pneumonia, Osteomyelitis)
- First-line: Cefazolin (preferred for ease of dosing and efficacy) 1
- Alternative: Antistaphylococcal penicillins (nafcillin or oxacillin) 2, 3
- Penicillin-allergic patients (non-anaphylactic): Cefazolin can still be used 3
- Immediate hypersensitivity to penicillins: Vancomycin 3
Recent evidence supports ceftriaxone as an alternative to standard antistaphylococcal antibiotics for MSSA, showing no difference in 90-day mortality, readmission, or recurrence rates, with lower toxicity (RR 0.49) 4. This makes ceftriaxone particularly attractive for outpatient parenteral therapy due to once-daily dosing.
Outpatient Skin and Soft Tissue Infections
- β-lactams: Cephalexin 500 mg PO QID or dicloxacillin 500 mg PO QID 5, 3
- Duration: 5-10 days based on clinical response 5
MRSA Treatment Algorithm
Invasive/Serious Infections
Bacteremia and Endocarditis:
- Vancomycin 15-20 mg/kg IV every 8-12 hours (target trough 15-20 mcg/mL) 5
- Daptomycin 6 mg/kg IV daily (AI evidence) - non-inferior to vancomycin 5, 1
- For prosthetic valve endocarditis: Add gentamicin + rifampin to vancomycin 5
Pneumonia:
- Vancomycin 15-20 mg/kg IV every 8-12 hours 5
- Linezolid 600 mg PO/IV BID (AI evidence) - may be superior for lung penetration 5
- Clindamycin 600 mg IV/PO TID (BIII evidence) 5
Complicated Skin and Soft Tissue Infections (Hospitalized):
- Vancomycin 15-20 mg/kg IV every 8-12 hours (AI evidence) 5
- Linezolid 600 mg PO/IV BID (AI evidence) 5
- Daptomycin 4 mg/kg IV daily (AI evidence) 5
- Telavancin 10 mg/kg IV daily (AI evidence) 5
- Clindamycin 600 mg IV/PO TID (AIII evidence) 5
- Duration: 7-14 days 5
Outpatient Skin and Soft Tissue Infections
Purulent cellulitis or abscesses requiring antibiotics:
- Clindamycin 300-450 mg PO TID (AI evidence) 5
- TMP-SMX 1-2 DS tablets PO BID (AII evidence) 5
- Doxycycline 100 mg PO BID (AII evidence) 5
- Linezolid 600 mg PO BID (AII evidence, but expensive) 5
- Duration: 5-10 days 5
Nonpurulent cellulitis:
- Start with β-lactam (e.g., cephalexin) for streptococcal coverage 5
- Add MRSA coverage if no response to β-lactam or systemic toxicity present 5
Critical Clinical Considerations
When Antibiotics Are Mandatory for Abscesses
Simple incision and drainage may suffice for uncomplicated abscesses, but antibiotics are required when 5:
- Multiple sites of infection or extensive disease
- Rapid progression with surrounding cellulitis
- Systemic illness signs (fever, hypotension, tachycardia)
- Immunosuppression or comorbidities (diabetes, HIV)
- Extremes of age
- Difficult drainage locations (face, hand, genitalia)
- Septic phlebitis
- Failed incision and drainage alone
Important Caveats
Clindamycin resistance: Check local resistance patterns; if >10% resistance rate, avoid empiric use 5. Clindamycin also carries higher risk of C. difficile infection 5.
TMP-SMX limitations:
- Pregnancy category C/D - avoid in third trimester 5
- Not for infants <2 months 5
- Hyperkalemia risk in elderly, especially with renal insufficiency or renin-angiotensin inhibitors 5
- No streptococcal coverage - combine with β-lactam if needed 5
Tetracyclines: Contraindicated in children <8 years and pregnancy (category D) 5
Rifampin: Never use as monotherapy or adjunctive therapy for SSTI due to rapid resistance development 5
Emerging resistance: Recent data show concerning non-susceptibility rates to linezolid (41%) and teicoplanin (15.7%) in some settings, though daptomycin maintains 96.3% susceptibility 6. This underscores the importance of culture-directed therapy when possible.
Source Control is Non-Negotiable
For all serious S. aureus infections, identify and address infection sources 1:
- Remove infected intravascular devices or implants
- Drain abscesses surgically
- Debride devitalized tissue
- Obtain echocardiography for all bacteremia cases (transthoracic minimum; transesophageal if persistent bacteremia, fever >72 hours, cardiac devices, or metastatic foci) 1
Prolonged bacteremia (≥48 hours) carries 39% 90-day mortality risk - aggressive source control and imaging for metastatic foci (endocarditis, vertebral osteomyelitis, epidural abscess) is mandatory 1.